119 related articles for article (PubMed ID: 14680437)
1. A comparison of current neuroblastoma chemotherapeutics.
Castel V; Cañete A
Expert Opin Pharmacother; 2004 Jan; 5(1):71-80. PubMed ID: 14680437
[TBL] [Abstract][Full Text] [Related]
2. Incorporation of high-dose
Lee JW; Lee S; Cho HW; Ma Y; Yoo KH; Sung KW; Koo HH; Cho EJ; Lee SK; Lim DH
J Hematol Oncol; 2017 May; 10(1):108. PubMed ID: 28511709
[TBL] [Abstract][Full Text] [Related]
3. [Value of prognostic factors in the Austrian A-NB87 Neuroblastoma Study].
Ladenstein R; Ambros PF; Urban C; Ambros IM; Fink FM; Zoubek A; Grienberger H; Schmitt K; Kerbl R; Horcher E; Amann G; Höfler G; Heinzl H; Gadner H; Mutz I
Klin Padiatr; 1996; 208(4):210-20. PubMed ID: 8926686
[TBL] [Abstract][Full Text] [Related]
4. Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry.
Ladenstein R; Philip T; Lasset C; Hartmann O; Garaventa A; Pinkerton R; Michon J; Pritchard J; Klingebiel T; Kremens B; Pearson A; Coze C; Paolucci P; Frappaz D; Gadner H; Chauvin F
J Clin Oncol; 1998 Mar; 16(3):953-65. PubMed ID: 9508178
[TBL] [Abstract][Full Text] [Related]
5. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique.
Rubie H; Hartmann O; Michon J; Frappaz D; Coze C; Chastagner P; Baranzelli MC; Plantaz D; Avet-Loiseau H; Bénard J; Delattre O; Favrot M; Peyroulet MC; Thyss A; Perel Y; Bergeron C; Courbon-Collet B; Vannier JP; Lemerle J; Sommelet D
J Clin Oncol; 1997 Mar; 15(3):1171-82. PubMed ID: 9060561
[TBL] [Abstract][Full Text] [Related]
6. Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the International Society of Paediatric Oncology European Neuroblastoma Experience.
Canete A; Gerrard M; Rubie H; Castel V; Di Cataldo A; Munzer C; Ladenstein R; Brichard B; Bermúdez JD; Couturier J; de Bernardi B; Pearson AJ; Michon J
J Clin Oncol; 2009 Mar; 27(7):1014-9. PubMed ID: 19171715
[TBL] [Abstract][Full Text] [Related]
7. Tandem high-dose chemotherapy and autologous stem cell transplantation in patients with high-risk neuroblastoma: results of SMC NB-2004 study.
Sung KW; Son MH; Lee SH; Yoo KH; Koo HH; Kim JY; Cho EJ; Lee SK; Choi YS; Lim DH; Kim JS; Kim DW
Bone Marrow Transplant; 2013 Jan; 48(1):68-73. PubMed ID: 22635247
[TBL] [Abstract][Full Text] [Related]
8. The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97.
Schmidt M; Simon T; Hero B; Schicha H; Berthold F
Eur J Cancer; 2008 Jul; 44(11):1552-8. PubMed ID: 18424129
[TBL] [Abstract][Full Text] [Related]
9. Is there a benefit of 131 I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004.
Schmidt M; Simon T; Hero B; Eschner W; Dietlein M; Sudbrock F; Bongartz R; Berthold F; Schicha H
Nuklearmedizin; 2006; 45(4):145-51; quiz N39-40. PubMed ID: 16964339
[TBL] [Abstract][Full Text] [Related]
10. High-dose chemotherapy followed by locoregional irradiation improves the outcome of patients with international neuroblastoma staging system Stage II and III neuroblastoma with MYCN amplification.
Laprie A; Michon J; Hartmann O; Munzer C; Leclair MD; Coze C; Valteau-Couanet D; Plantaz D; Carrie C; Habrand JL; Bergeron C; Chastagner P; Défachelles AS; Delattre O; Combaret V; Bénard J; Pérel Y; Gandemer V; Rubie H;
Cancer; 2004 Sep; 101(5):1081-9. PubMed ID: 15329919
[TBL] [Abstract][Full Text] [Related]
11. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study.
Schmidt ML; Lal A; Seeger RC; Maris JM; Shimada H; O'Leary M; Gerbing RB; Matthay KK
J Clin Oncol; 2005 Sep; 23(27):6474-80. PubMed ID: 16116154
[TBL] [Abstract][Full Text] [Related]
12. Feasibility, toxicity and response of upfront metaiodobenzylguanidine therapy therapy followed by German Pediatric Oncology Group Neuroblastoma 2004 protocol in newly diagnosed stage 4 neuroblastoma patients.
Kraal KC; Bleeker GM; van Eck-Smit BL; van Eijkelenburg NK; Berthold F; van Noesel MM; Caron HN; Tytgat GA
Eur J Cancer; 2017 May; 76():188-196. PubMed ID: 28329731
[TBL] [Abstract][Full Text] [Related]
13. Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age.
de Kraker J; Hoefnagel KA; Verschuur AC; van Eck B; van Santen HM; Caron HN
Eur J Cancer; 2008 Mar; 44(4):551-6. PubMed ID: 18267358
[TBL] [Abstract][Full Text] [Related]
14. [Management strategy in neuroblastoma].
Balwierz W
Przegl Lek; 2004; 61 Suppl 2():3-8. PubMed ID: 15686038
[TBL] [Abstract][Full Text] [Related]
15. Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children's Cancer Group studies.
Stram DO; Matthay KK; O'Leary M; Reynolds CP; Haase GM; Atkinson JB; Brodeur GM; Seeger RC
J Clin Oncol; 1996 Sep; 14(9):2417-26. PubMed ID: 8823319
[TBL] [Abstract][Full Text] [Related]
16. Stage III neuroblastoma over 1 year of age at diagnosis: improved survival with intensive multimodality therapy including multiple alkylating agents.
West DC; Shamberger RC; Macklis RM; Kozakewich HP; Wayne AS; Kreissman SG; Korf BR; Lavally B; Grier HE
J Clin Oncol; 1993 Jan; 11(1):84-90. PubMed ID: 8418247
[TBL] [Abstract][Full Text] [Related]
17. Improved survival of children with advanced neuroblastoma treated by intensified therapy including myeloablative chemotherapy with stem cell transplantation: a retrospective analysis from the Tohoku Neuroblastoma Study Group.
Imaizumi M; Watanabe A; Kikuta A; Takano T; Ito E; Shimizu T; Tsuchiya S; Iinuma K; Konno T; Ohi R; Hayashi Y;
Tohoku J Exp Med; 2001 Oct; 195(2):73-83. PubMed ID: 11846211
[TBL] [Abstract][Full Text] [Related]
18. 131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma.
French S; DuBois SG; Horn B; Granger M; Hawkins R; Pass A; Plummer E; Matthay K
Pediatr Blood Cancer; 2013 May; 60(5):879-84. PubMed ID: 23024113
[TBL] [Abstract][Full Text] [Related]
19. Treatment of neuroblastoma stage 4 with 131I-meta-iodo-benzylguanidine, high-dose chemotherapy and immunotherapy. A pilot study.
Klingebiel T; Bader P; Bares R; Beck J; Hero B; Jürgens H; Lang P; Niethammer D; Rath B; Handgretinger R
Eur J Cancer; 1998 Aug; 34(9):1398-402. PubMed ID: 9849423
[TBL] [Abstract][Full Text] [Related]
20. [Comprehensive protocol for diagnosis and treatment of childhood neuroblastoma--results of 45 cases].
Tang JY; Pan C; Chen J; Xu M; Chen J; Xue HL; Gu LJ; Dong R; Ye H; Zhou M; Wang YP
Zhonghua Er Ke Za Zhi; 2006 Oct; 44(10):770-3. PubMed ID: 17229383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
